ALK and cancer: Molecular targeted therapies for specific genomic alterations, such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements, are among the greatest innovations in the field of personalized cancer therapy.